{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:39:45Z","timestamp":1790167185089,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1471-2407-13-612","type":"journal-article","created":{"date-parts":[[2013,12,28]],"date-time":"2013-12-28T20:01:23Z","timestamp":1388260883000},"source":"Crossref","is-referenced-by-count":20,"title":["Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites"],"prefix":"10.1186","volume":"13","author":[{"given":"Nynke GL","family":"Jager","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutger HT","family":"Koornstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron HN","family":"van Schaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin DR","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiny M","family":"Korse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan HM","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine C","family":"Linn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos H","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,12,28]]},"reference":[{"issue":"9472","key":"4229_CR1","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365 (9472): 1687-1717.","journal-title":"Lancet"},{"issue":"4","key":"4229_CR2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1677\/erc.1.00776","volume":"11","author":"A Ring","year":"2004","unstructured":"Ring A, Dowsett M: Mechanisms of tamoxifen resistance. Endocr Relat Cancer. 2004, 11 (4): 643-658. 10.1677\/erc.1.00776.","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"4229_CR3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nrclinonc.2012.121","volume":"9","author":"K Beelen","year":"2012","unstructured":"Beelen K, Zwart W, Linn SC: Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?. Nat Rev Clin Oncol. 2012, 9 (9): 529-541. 10.1038\/nrclinonc.2012.121.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"4229_CR4","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00280-004-0926-7","volume":"55","author":"YC Lim","year":"2005","unstructured":"Lim YC, Desta Z, Flockhart DA, Skaar TC: Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol. 2005, 55 (5): 471-478. 10.1007\/s00280-004-0926-7.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"4229_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1023\/B:BREA.0000025406.31193.e8","volume":"85","author":"MD Johnson","year":"2004","unstructured":"Johnson MD, Zuo H, Lee K-H, Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA, Skaar TC: Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat. 2004, 85 (2): 151-159. 10.1023\/B:BREA.0000025406.31193.e8.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"4229_CR6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10549-011-1428-z","volume":"131","author":"WJ Lu","year":"2012","unstructured":"Lu WJ, Desta Z, Flockhart DA: Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer. Breast Cancer Res Treat. 2012, 131 (2): 473-481. 10.1007\/s10549-011-1428-z.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"4229_CR7","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.jpba.2011.02.009","volume":"55","author":"SF Teunissen","year":"2011","unstructured":"Teunissen SF, Rosing H, Seoane MD, Brunsveld L, Schellens JHM, Schinkel AH, Beijnen JH: Investigational study of tamoxifen phase I metabolites using chromatographic and spectroscopic analytical techniques. J Pharm Biomed Anal. 2011, 55 (3): 518-526. 10.1016\/j.jpba.2011.02.009.","journal-title":"J Pharm Biomed Anal"},{"issue":"5","key":"4229_CR8","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/clpt.2011.32","volume":"89","author":"L Madlensky","year":"2011","unstructured":"Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, Nikoloff DM, Hillman G, Fontecha MR, Lawrence HJ, et al: Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011, 89 (5): 718-725. 10.1038\/clpt.2011.32.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"4229_CR9","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/clpt.2011.153","volume":"90","author":"MF Barginear","year":"2011","unstructured":"Barginear MF, Jaremko M, Peter I, Yu C, Kasai Y, Kemeny M, Raptis G, Desnick RJ: Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score. Clin Pharmacol Ther. 2011, 90 (4): 605-611. 10.1038\/clpt.2011.153.","journal-title":"Clin Pharmacol Ther"},{"issue":"24","key":"4229_CR10","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1200\/JCO.2010.31.4427","volume":"29","author":"WJ Irvin Jr","year":"2011","unstructured":"Irvin WJ, Walko CM, Weck KE, Ibrahim JG, Chiu WK, Dees EC, Moore SG, Olajide OA, Graham ML, Canale ST, et al: Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol. 2011, 29 (24): 3232-3239. 10.1200\/JCO.2010.31.4427.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4229_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/jnci\/dji005","volume":"97","author":"Y Jin","year":"2005","unstructured":"Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee K-H, Skaar T, Storniolo AM, Li L, Araba A, et al: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005, 97 (1): 30-39. 10.1093\/jnci\/dji005.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"4229_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/jnci\/djs126","volume":"104","author":"JM Rae","year":"2012","unstructured":"Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M, et al: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012, 104 (6): 452-460. 10.1093\/jnci\/djs126.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"4229_CR13","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/jnci\/djs125","volume":"104","author":"MM Regan","year":"2012","unstructured":"Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell\u2019orto P, Biasi MO, Th\u00fcrlimann B, Lyng MB, et al: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1\u201398 trial. J Natl Cancer Inst. 2012, 104 (6): 441-451. 10.1093\/jnci\/djs125.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"4229_CR14","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1200\/JCO.2012.44.6625","volume":"31","author":"H Brauch","year":"2012","unstructured":"Brauch H, Schroth W, Goetz MP, M\u00fcrdter TE, Winter S, Ingle JN, Schwab M, Eichelbaum M: Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol. 2012, 31 (2): 176-180.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4229_CR15","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/annonc\/mdq387","volume":"22","author":"K Potthoff","year":"2011","unstructured":"Potthoff K, Hofheinz R, Hassel JC, Volkenandt M, Lordick F, Hartmann JT, Karthaus M, Riess H, Lipp HP, Hauschild A, et al: Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol. 2011, 22 (3): 524-535. 10.1093\/annonc\/mdq387.","journal-title":"Ann Oncol"},{"issue":"21","key":"4229_CR16","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/jnci\/88.21.1529","volume":"88","author":"B Fisher","year":"1996","unstructured":"Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, et al: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996, 88 (21): 1529-1542. 10.1093\/jnci\/88.21.1529.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"4229_CR17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3816\/CBC.2000.n.004","volume":"1","author":"CL Loprinzi","year":"2000","unstructured":"Loprinzi CL, Zahasky KM, Sloan JA, Novotny PJ, Quella SK: Tamoxifen-induced hot flashes. Clin Breast Cancer. 2000, 1 (1): 52-56. 10.3816\/CBC.2000.n.004.","journal-title":"Clin Breast Cancer"},{"issue":"8","key":"4229_CR18","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/jnci\/85.8.673-a","volume":"85","author":"RR Love","year":"1993","unstructured":"Love RR, Feyzi JM: Reduction in vasomotor symptoms from tamoxifen over time. J Natl Cancer Inst. 1993, 85 (8): 673-674.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"4229_CR19","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10549-007-9612-x","volume":"108","author":"JE Mortimer","year":"2008","unstructured":"Mortimer JE, Flatt SW, Parker BA, Gold EB, Wasserman L, Natarajan L, Pierce JP, WHEL Study Group: Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat. 2008, 108 (3): 421-426. 10.1007\/s10549-007-9612-x.","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"4229_CR20","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/S1470-2045(08)70259-6","volume":"9","author":"J Cuzick","year":"2008","unstructured":"Cuzick J, Sestak I, Cella D, Fallowfield L, ATAC Trialists\u2019 Group: Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol. 2008, 9 (12): 1143-1148. 10.1016\/S1470-2045(08)70259-6.","journal-title":"Lancet Oncol"},{"issue":"29","key":"4229_CR21","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1200\/JCO.2010.33.1298","volume":"29","author":"AH Boekhout","year":"2011","unstructured":"Boekhout AH, Vincent AD, Dalesio OB, van den Bosch J, Foekema-T\u00f6ns JH, Adriaansz S, Sprangers S, Nuijen B, Beijnen JH, Schellens JHM: Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2011, 29 (29): 3862-3868. 10.1200\/JCO.2010.33.1298.","journal-title":"J Clin Oncol"},{"issue":"23","key":"4229_CR22","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1200\/JCO.2001.19.23.4280","volume":"19","author":"JA Sloan","year":"2001","unstructured":"Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H: Methodologic lessons learned from hot flash studies. J Clin Oncol. 2001, 19 (23): 4280-4290.","journal-title":"J Clin Oncol"},{"key":"4229_CR23","unstructured":"Wet Medisch-wetenschappelijk Onderzoek met mensen - (Dutch Act on medical research involving human beings, February 26, 1998). [ http:\/\/wetten.overheid.nl\/BWBR0009408 ]"},{"issue":"19","key":"4229_CR24","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/j.jchromb.2011.04.011","volume":"879","author":"SF Teunissen","year":"2011","unstructured":"Teunissen SF, Jager NGL, Rosing H, Schinkel AH, Schellens JHM, Beijnen JH: Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2011, 879 (19): 1677-1685. 10.1016\/j.jchromb.2011.04.011.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"4229_CR25","volume-title":"Guideline on bioanalytical method validation","author":"European_Medicines_Agency","year":"2011","unstructured":"European_Medicines_Agency: Guideline on bioanalytical method validation. 2011, London(UK): EMEA"},{"key":"4229_CR26","volume-title":"Bioanalytical Method Validation","author":"Food_and_Drug_Administration","year":"2001","unstructured":"Food_and_Drug_Administration: Bioanalytical Method Validation. 2001, Rockville, MD (USA): FDA"},{"issue":"6","key":"4229_CR27","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/sj.bjc.6605800","volume":"103","author":"LA Lammers","year":"2010","unstructured":"Lammers LA, Mathijssen RHJ, van Gelder T, Bijl MJ, de Graan A-JM, Seynaeve C, van Fessem MA, Berns EM, Vulto AG, van Schaik RHN: The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. Br J Cancer. 2010, 103 (6): 765-771. 10.1038\/sj.bjc.6605800.","journal-title":"Br J Cancer"},{"issue":"3","key":"4229_CR28","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s10549-011-1893-4","volume":"132","author":"W Lorizio","year":"2012","unstructured":"Lorizio W, Wu AHB, Beattie MS, Rugo H, Tchu S, Kerlikowske K, Ziv E: Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat. 2012, 132 (3): 1107-1118. 10.1007\/s10549-011-1893-4.","journal-title":"Breast Cancer Res Treat"},{"issue":"24","key":"4229_CR29","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1200\/JCO.2005.04.3745","volume":"24","author":"I Sestak","year":"2006","unstructured":"Sestak I, Kealy R, Edwards R, Forbes J, Cuzick J: Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms. J Clin Oncol. 2006, 24 (24): 3991-3996. 10.1200\/JCO.2005.04.3745.","journal-title":"J Clin Oncol"},{"issue":"36","key":"4229_CR30","doi-asserted-by":"publisher","first-page":"9312","DOI":"10.1200\/JCO.2005.03.3266","volume":"23","author":"MP Goetz","year":"2005","unstructured":"Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, et al: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005, 23 (36): 9312-9318. 10.1200\/JCO.2005.03.3266.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4229_CR31","first-page":"403","volume":"59","author":"Y Erlik","year":"1982","unstructured":"Erlik Y, Meldrum DR, Judd HL: Estrogen levels in postmenopausal women with hot flashes. Obstet Gynecol. 1982, 59 (4): 403-407.","journal-title":"Obstet Gynecol"},{"issue":"3","key":"4229_CR32","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/0029-7844(96)00196-2","volume":"88","author":"JR Guthrie","year":"1996","unstructured":"Guthrie JR, Dennerstein L, Hopper JL, Burger HG: Hot flushes, menstrual status, and hormone levels in a population-based sample of midlife women. Obstet Gynecol. 1996, 88 (3): 437-442. 10.1016\/0029-7844(96)00196-2.","journal-title":"Obstet Gynecol"},{"issue":"7","key":"4229_CR33","doi-asserted-by":"publisher","first-page":"1380S","DOI":"10.3945\/jn.109.120840","volume":"140","author":"F Kronenberg","year":"2010","unstructured":"Kronenberg F: Menopausal hot flashes: a review of physiology and biosociocultural perspective on methods of assessment. J Nutr. 2010, 140 (7): 1380S-1385S. 10.3945\/jn.109.120840.","journal-title":"J Nutr"},{"issue":"6","key":"4229_CR34","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1097\/01.AOG.0000187308.67021.98","volume":"106","author":"K Visvanathan","year":"2005","unstructured":"Visvanathan K, Gallicchio L, Schilling C, Babus JK, Lewis LM, Miller SR, Zacur H, Flaws JA: Cytochrome gene polymorphisms, serum estrogens, and hot flushes in midlife women. Obstet Gynecol. 2005, 106 (6): 1372-1381. 10.1097\/01.AOG.0000187308.67021.98.","journal-title":"Obstet Gynecol"},{"issue":"4","key":"4229_CR35","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.maturitas.2010.08.007","volume":"67","author":"J Moilanen","year":"2010","unstructured":"Moilanen J, Aalto AM, Hemminki E, Aro AR, Raitanen J, Luoto R: Prevalence of menopause symptoms and their association with lifestyle among Finnish middle-aged women. Maturitas. 2010, 67 (4): 368-374. 10.1016\/j.maturitas.2010.08.007.","journal-title":"Maturitas"},{"issue":"5","key":"4229_CR36","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/AOG.0b013e318214f0de","volume":"117","author":"EW Freeman","year":"2011","unstructured":"Freeman EW, Sammel MD, Lin H, Liu Z, Gracia CR: Duration of menopausal hot flushes and associated risk factors. Obstetrics & Gynecology. 2011, 117 (5): 1095-1104. 10.1097\/AOG.0b013e318214f0de.","journal-title":"Obstetrics & Gynecology"},{"issue":"10","key":"4229_CR37","doi-asserted-by":"publisher","first-page":"E1588","DOI":"10.1210\/jc.2011-1082","volume":"96","author":"RC Thurston","year":"2011","unstructured":"Thurston RC, Santoro N, Matthews KA: Adiposity and hot flashes in midlife women: a modifying role of age. J Clin Endocrinol Metab. 2011, 96 (10): E1588-E1595. 10.1210\/jc.2011-1082.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"4229_CR38","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.maturitas.2011.09.011","volume":"70","author":"B Gjelsvik","year":"2011","unstructured":"Gjelsvik B, Rosvold EO, Straand J, Dalen I, Hunskaar S: Symptom prevalence during menopause and factors associated with symptoms and menopausal age. Results from the Norwegian Hordaland Women\u2019s Cohort study. Maturitas. 2011, 70 (4): 383-390. 10.1016\/j.maturitas.2011.09.011.","journal-title":"Maturitas"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-612.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-13-612\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-612","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T05:00:28Z","timestamp":1498107628000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-13-612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["4229"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-13-612","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12]]},"article-number":"612"}}